Wedmont Private Capital Takes $361,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Wedmont Private Capital purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) in the fourth quarter, Holdings Channel reports. The firm purchased 1,644 shares of the medical research company’s stock, valued at approximately $361,000.

Other institutional investors have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Charles River Laboratories International by 417.3% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,288 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,039 shares during the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Charles River Laboratories International by 49.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 8,923 shares of the medical research company’s stock valued at $1,909,000 after acquiring an additional 2,951 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Charles River Laboratories International by 9.3% in the 2nd quarter. Federated Hermes Inc. now owns 212,868 shares of the medical research company’s stock valued at $45,547,000 after acquiring an additional 18,196 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Charles River Laboratories International by 1.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 103,472 shares of the medical research company’s stock valued at $20,364,000 after acquiring an additional 1,539 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Charles River Laboratories International by 7.2% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 9,148 shares of the medical research company’s stock valued at $1,801,000 after acquiring an additional 613 shares during the last quarter. 97.80% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 0.3 %

Shares of CRL stock opened at $192.92 on Friday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.08 and a current ratio of 1.32. Charles River Laboratories International, Inc. has a 1 year low of $181.36 and a 1 year high of $308.15. The stock has a fifty day moving average of $233.82 and a two-hundred day moving average of $220.85. The firm has a market capitalization of $9.84 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 1.36 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.75 by $0.23. Charles River Laboratories International had a return on equity of 20.98% and a net margin of 12.23%. The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the firm posted $2.49 EPS. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 10.25 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. Guggenheim upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $255.00 price target for the company in a report on Thursday, February 23rd. Morgan Stanley lowered their price objective on Charles River Laboratories International from $241.00 to $230.00 and set an “equal weight” rating for the company in a research note on Thursday, February 23rd. StockNews.com assumed coverage on Charles River Laboratories International in a research note on Thursday. They set a “hold” rating for the company. Citigroup lowered their price objective on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating for the company in a research note on Thursday, February 23rd. Finally, Robert W. Baird upped their price objective on Charles River Laboratories International from $275.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $270.83.

Insiders Place Their Bets

In other news, CEO James C. Foster sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $250.00, for a total value of $5,000,000.00. Following the completion of the sale, the chief executive officer now owns 216,594 shares in the company, valued at $54,148,500. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Shannon M. Parisotto sold 4,558 shares of the company’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $254.41, for a total value of $1,159,600.78. Following the completion of the sale, the executive vice president now owns 6,010 shares in the company, valued at $1,529,004.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James C. Foster sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $250.00, for a total value of $5,000,000.00. Following the completion of the sale, the chief executive officer now owns 216,594 shares of the company’s stock, valued at approximately $54,148,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,763 shares of company stock worth $6,974,921. 1.10% of the stock is owned by company insiders.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.